Abstract:

Oral cancer is currently the sixth most common carcinoma worldwide and  squamous-cell carcinoma accounts for more than 90 % of all cases. The earliest diagnosis of squamous-cell carcinoma, the better the outcome of the treatment and the prognosis. The choice of treatment depends on tumour stage. Most early squamous-cell carcinoma cases are amenable to surgical curative treatment while advanced cases commonly receive combined palliative therapy. Despite recent advance in medicine, survival rates in these patients are rarely higher than 5 years and prognosis remains poor. Our aim in this paper is to present the latest treatment options for oral squamous cell carcinoma  emphasizing the monoclonal antibody therapy, oncolytic virotherapy and immunotherapy with IL2.